MAPT and Alzheimer disease: We previously showed that the brains of these same AD transgenic mice treated with 2-month oral simufilam showed reduced FLNA linkages with α7nAChR and TLR4, reduced tau hyperphosphorylation, reduced inflammatory cytokine levels, reduced amyloid deposits and neurofibrillary lesions, improved function of NMDA and insulin receptors, and improved activity-dependent Arc expression (an indicator of synaptic plasticity) [10].